Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1L1 | Q9UHC9 | 5/20 | 0.66 |
| ▸ | USP2 | O75604 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | CDC25A | P30304 | 4/20 | 0.55 |
| ▸ | CDC25B | P30305 | 1/20 | 0.55 |
| ▸ | INPP5D | Q92835 | 1/20 | 0.54 |
| ▸ | FNTA | P49354 | 2/20 | 0.54 |
| ▸ | FNTB | P49356 | 2/20 | 0.54 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
| ▸ | OSBP | P22059 | 1/20 | 0.50 |
| ▸ | RORC | P51449 | 1/20 | 0.50 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.50 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2637544 | 1.00 | NPC1L1 (0.66) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL11793322 | 0.88 | OSBP (0.60) | NPC1L1OSBPRORCOSBP2 | |
| SCHEMBL11793318 | 0.88 | OSBP (0.60) | NPC1L1OSBPRORCOSBP2 | |
| SCHEMBL11784621 | 0.87 | NPC1L1 (0.70) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL5059482 | 0.86 | NPC1L1 (0.49) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL27573811 | 0.86 | NPC1L1 (0.62) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL14490143 | 0.86 | NPC1L1 (0.71) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL6900370 | 0.86 | NPC1L1 (0.71) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL26642903 | 0.86 | NPC1L1 (0.71) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL7117000 | 0.86 | NPC1L1 (0.71) | NPC1L1USP2LMNAMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4025196-A1 | LIPID NANOPARTICLE COMPOSITIONS COMPRISING CLOSED-ENDED DNA AND CLEAVABLE LIPIDS AND METHODS OF USE THEREOF | Generation Bio Co. (US) | 2022-07-13 | — | — | EP | disclosed |
| WO-2021046265-A1 | LIPID NANOPARTICLE COMPOSITIONS COMPRISING CLOSED-ENDED DNA AND CLEAVABLE LIPIDS AND METHODS OF USE THEREOF | GENERATION BIO CO. (US) | 2021-03-11 | — | — | WO | disclosed |
| EP-3720952-A1 | GENE EDITING USING A MODIFIED CLOSED-ENDED DNA (CEDNA) | Generation Bio Co. (US) | 2020-10-14 | — | — | EP | disclosed |
| WO-2019113310-A1 | GENE EDITING USING A MODIFIED CLOSED-ENDED DNA (CEDNA) | GENERATION BIO CO. (US) | 2019-06-13 | — | — | WO | disclosed |
| WO-2019051257-A2 | METHODS FOR TREATING HEPATITIS B INFECTIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-03-14 | — | — | WO | disclosed |
| EP-3329003-A2 | COMPOSITIONS AND METHODS FOR SILENCING HEPATITIS B VIRUS GENE EXPRESSION | Arbutus Biopharma Corporation (CA) | 2018-06-06 | — | — | EP | disclosed |
| WO-2017019891-A2 | COMPOSITIONS AND METHODS FOR SILENCING HEPATITIS B VIRUS GENE EXPRESSION | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2017-02-02 | — | — | WO | disclosed |
| WO-2016071857-A1 | COMPOSITIONS AND METHODS FOR SILENCING EBOLA VIRUS EXPRESSION | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2016-05-12 | — | — | WO | disclosed |
| EP-2764007-A1 | COMPOSITIONS AND METHODS FOR SILENCING ALDEHYDE DEHYDROGENASE | Protiva Biotherapeutics Inc. (CA) | 2014-08-13 | — | — | EP | disclosed |
| WO-2013052677-A1 | COMPOSITIONS AND METHODS FOR SILENCING ALDEHYDE DEHYDROGENASE | PROTIVA BIOTHERAPEUTICS INC. (CA) | 2013-04-11 | — | — | WO | disclosed |
| WO-2011141703-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | PROTIVA BIOTHERAPEUTICS INC. (CA) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011141704-A1 | NOVEL CYCLIC CATIONIC LIPIDS AND METHODS OF USE | PROTIVA BIOTHERAPEUTICS, INC (CA) | 2011-11-17 | — | — | WO | disclosed |